Moderna, Inc.'s stock plummets as challenges mount, including vaccine skepticism, competitive pressures, and the RFK ...

Moderna (MRNA) stock has fallen 71% over the last six months. While there’s still potential for near-term revenue tailwinds ...

KEY TAKEAWAYS Moderna shares surged further Friday, a day after a senior executive made bullish comments at a healthcare ...

Analyst Michael Yee from Jefferies maintained a Hold rating on Moderna (MRNA – Research Report) and decreased the price target to $50.00 from $55.00. Don't Miss our Black Friday Offers: Unlock your ...

Shares of Moderna Inc. (NASDAQ: MRNA) are trading lower after President-elect Donald Trump nominated Robert F. Kennedy Jr. to ...

CNBC's Jim Cramer reports on the latest news regarding Moderna.

Trump said during a rally in late October that he would let Kennedy “go wild” on healthcare in the country, and vaccine ...

Moderna plans to prioritize new product approvals and oncology investments, as political concerns over Robert F. Kennedy Jr.'s HHS nomination weigh on vaccine stocks.

Coegi used more than 500 million impressions and paid social optimized with attention and emotion metrics to drive 24% of ...

Moderna had a negative net margin of 43.77% and a negative return on equity of 17.68%. The firm had revenue of $1.90 billion during the quarter, compared to the consensus estimate of $1.25 billion.

Berenberg has initiated coverage of BioNTech (BNTX) and Moderna (MRNA), citing their leadership positions in mRNA medicine.